Association of adolescent and young adult cancer treatment trial activity with a national mortality reduction benefit in the United States

6605 Background: Adolescent and young adult (AYA) cancer patients in the U.S. have had less mortality and survival improvement than have children or older adults with cancer. Because <3% of 20–35 year-olds are entered onto national cancer treatment trials (NCTT), in contrast to ∼50% of children, initiatives were undertaken during the past 6 years to increase NCTT AYA participation. Methods: NCTT accrual data were obtained from the Cancer Treatment Evaluation Program, NCI. Survival, mortality, and incidence data were obtained from the NCI Surveillance, Epidemiology, and End Results (SEER) program. Results: In comparison of 2002–2006 with 1996–2001, the average annual NCCT accruals of patients 15–39 years of age increased from 1,032 to 1,792, the estimated proportion of patients in this age group on NCTT increased from an average of 4.2% to 6.5%, and the proportion of all NCCT accruals (of all ages) that were in the 15–39 year age group increased from an average of 5.2% to 8.2%. Of the 11 national NCTT grou...